![]() ✝Patients with previous treatment failure and cirrhosis may have lower response rates.✝GT 1a with cirrhosis has lower response if NS5A polymorphism is present.HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.✝Treatment-experienced patients have failed an interferon based regimen with or without ribavirin.No cirrhosis or Child-Pugh A: See Vosevi.Retreatment of HCV genotype 1, 2, 3, 4, 5, and 6 in patients who failed previous treatment with an NS5A inhibitor or sofosbuvir.See Epclusa for another regimen that includes sofosbuvir.See Epclusa for other regimens that include sofosbuvir.Treatment-naïve and treatment-experienced ✝, no cirrhosis or Child-Pugh A: Sofosbuvir + RBV.See Epclusa and Harvoni for other regimens that include sofosbuvir.Treatment-naïve, no cirrhosis or Child-Pugh A: Sofosbuvir + RBV + PegIFN (no longer recommended).Illustration of mechanism of action of hepatitis C drugs.Which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203),.Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication.See Hepatitis C treatment for a list of other HCV drugs.Sofosbuvir is available by itself, and it is also found in the combination pills Epclusa and Harvoni.Sofosbuvir is part of a new generation of antiviral medications that are highly effective against hepatitis C.IDSA - Infectious Diseases Society of America.CP - Child-Pugh liver failure classification.AASLD - American Association for the Study of Liver Diseases.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |